+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Antidiuretic Drugs Market 2019-2023 - Product Image

Global Antidiuretic Drugs Market 2019-2023

  • ID: 4760035
  • Report
  • March 2019
  • Region: Global
  • 121 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Avadel
  • CSL Limited
  • Ferring B.V.
  • Novartis AG
  • Sanofi
  • MORE
With the rapid onset of modernization, the lifestyle of people is also changing. The prevalence of such health conditions is rising globally due to the sedentary lifestyle. Furthermore, the high prevalence of conditions such as urinary incontinence and interstitial cystitis has been substantially contributing to the global antidiuretic drugs market.

According to the CDC, the prevalence of nocturia in the US during 2013-2014 was found to be nearly 25% of the population. and the prevalence rate increased to about 40% in the people affected with chronic kidney diseases. Such a high prevalence of chronic conditions leads to polyuria and nocturia, which, in turn, will help in driving the global antidiuretic drugs market. The analysts have predicted that the antidiuretic drugs market will register a CAGR of almost 10% by 2023.

Market Overview

Rising geriatric population

The prevalence of chronic conditions that lead to various urologic diseases, including polyuria and nocturia, increases with age, and these conditions are prevalent in the geriatric population. Furthermore, rapid developments in the healthcare facilities and advanced treatment options have increased the life expectancy of the geriatric population globally. Rising awareness about various health conditions has been substantially contributing to the higher life expectancy.

Stringent regulator policies

One of the major challenges faced by the pharmaceutical vendors is the stringent policies set by various regulatory bodies and governing authorities globally. The US FDA has increased the regulatory surveillance for the drugs treating rare diseases, to avoid any associated risks. Hence, the disappointing results in drugs performance lead to the postponement of marketing approvals, which, further hampers the market growth.

For the detailed list of factors that will drive and challenge the growth of the antidiuretic drugs market during the 2019-2023, view this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avadel
  • CSL Limited
  • Ferring B.V.
  • Novartis AG
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Autoimmune diseases - Market size and forecast 2018-2023
  • Urologic diseases - Market size and forecast 2018-2023
  • Other applications - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Avadel
  • CSL Limited
  • Ferring B.V.
  • Novartis AG
  • Sanofi
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Applications of antidiuretic drugs
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Autoimmune diseases - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Autoimmune diseases - Year-over-year growth 2019-2023 (%)
Exhibit 22: Urologic diseases - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Urologic diseases - Year-over-year growth 2019-2023 (%)
Exhibit 24: Other applications - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other applications - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Prevalence of diabetes in European countries 2017
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Europe
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Asia
Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in ROW
Exhibit 43: Market opportunity
Exhibit 44: Growth in geriatric population 2013-2017 (%)
Exhibit 45: Awareness programs related to chronic conditions
Exhibit 46: Adverse effects of desmopressin and vasopressin
Exhibit 47: Pipeline drugs
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Patient assistance programs
Exhibit 50: Approved desmopressin analogs
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: Avadel - Vendor overview
Exhibit 57: Avadel - Business segments
Exhibit 58: Avadel - Organizational developments
Exhibit 59: Avadel - Geographic focus
Exhibit 60: Avadel - Key offerings
Exhibit 61: Avadel - Key customers
Exhibit 62: CSL Limited - Vendor overview
Exhibit 63: CSL Limited - Business segments
Exhibit 64: CSL Limited - Organizational developments
Exhibit 65: CSL Limited - Geographic focus
Exhibit 66: CSL Limited - Segment focus
Exhibit 67: CSL Limited - Key offerings
Exhibit 68: CSL Limited - Key customers
Exhibit 69: Ferring B.V. - Vendor overview
Exhibit 70: Ferring B.V. - Service segments
Exhibit 71: Ferring B.V. - Organizational developments
Exhibit 72: Ferring B.V. - Geographic focus
Exhibit 73: Ferring B.V. - Segment focus
Exhibit 74: Ferring B.V. - Key offerings
Exhibit 75: Ferring B.V. - Key customers
Exhibit 76: Novartis AG - Vendor overview
Exhibit 77: Novartis AG - Business segments
Exhibit 78: Novartis AG - Organizational developments
Exhibit 79: Novartis AG - Geographic focus
Exhibit 80: Novartis AG - Segment focus
Exhibit 81: Novartis AG - Key offerings
Exhibit 82: Novartis AG - Key customers
Exhibit 83: Sanofi - Vendor overview
Exhibit 84: Sanofi - Business segments
Exhibit 85: Sanofi - Organizational developments
Exhibit 86: Sanofi - Geographic focus
Exhibit 87: Sanofi - Segment focus
Exhibit 88: Sanofi - Key offerings
Exhibit 89: Sanofi - Key customers
Exhibit 90: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Avadel
  • CSL Limited
  • Ferring B.V.
  • Novartis AG
  • Sanofi
  • MORE
Global Antidiuretic Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global antidiuretic drugs market: Avadel, CSL Limited, Ferring B.V., Novartis AG, Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the generic drugs is expected to hamper the revenue growth of the market.”

According to the report, one of the major drivers for this market is the awareness programs help patients know about the symptoms, diagnosis and treatment options related to the diseases and to augment the growth of the market.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of the currently available antidiuretic drugs are expected to limit the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Avadel
  • CSL Limited
  • Ferring B.V.
  • Novartis AG
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll